BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 23889174)

  • 21. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
    de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
    J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
    Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
    Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
    Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
    Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
    Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
    Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
    Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.
    Chen XY; Thike AA; Koh VCY; Nasir NDM; Bay BH; Tan PH
    Virchows Arch; 2021 Apr; 478(4):679-686. PubMed ID: 33140128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
    Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
    Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
    Cefaro GA; Genovesi D; Trignani M; DI Nicola M
    Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cytoplasmic expression of aquaporin-1 in breast cancer cells and its relationship with clinicopathological characteristics and prognosis].
    Zhang B; Liu FF; Ma YJ; Gu F
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):904-9. PubMed ID: 24506959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of myofibroblast cells and microvessels around invasive ductal carcinoma of the breast and comparing with the adjacent range of their normal-to-DCIS zones.
    Dabiri S; Talebi A; Shahryari J; Meymandi MS; Safizadeh H
    Arch Iran Med; 2013 Feb; 16(2):93-9. PubMed ID: 23360631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
    Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study.
    Provenzano E; Hopper JL; Giles GG; Marr G; Venter DJ; Armes JE
    Pathology; 2004 Jun; 36(3):221-9. PubMed ID: 15203725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast.
    Agahozo MC; van Bockstal M; Westenend PJ; Galant C; Lambein K; Reisenbichler E; Sinke R; Wong S; van Deurzen CHM
    J Mammary Gland Biol Neoplasia; 2021 Dec; 26(4):367-375. PubMed ID: 35076865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery.
    Boland GP; Chan KC; Knox WF; Roberts SA; Bundred NJ
    Br J Surg; 2003 Apr; 90(4):426-32. PubMed ID: 12673743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.